DDInter1202 DDInter927
Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Metronidazole {u} (Compound) resembles {v} (Compound) Tinidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C8
Metronidazole {u} (Compound) upregulates {v} (Gene) ZNF586
Metronidazole {u} (Compound) is included by {v} (Pharmacologic Class) Nitroimidazoles
Metronidazole {u} (Compound) causes {v} (Side Effect) Loss of libido
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Atomoxetine
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tetrabenazine
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telbivudine
Metronidazole {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Metronidazole (Compound) resembles Tinidazole (Compound)
Metronidazole (Compound) binds CYP2C8 (Gene)
Metronidazole (Compound) upregulates ZNF586 (Gene)
Metronidazole (Compound) is included by Nitroimidazoles (Pharmacologic Class)
Metronidazole (Compound) causes Loss of libido (Side Effect)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Atomoxetine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tetrabenazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Metronidazole may lead to a major life threatening interaction when taken with Amprenavir